Sobi opens North American operations
(Thomson Reuters ONE) -
Swedish Orphan Biovitrum AB (publ) (Sobi) today formally opened the company's
new North American office in Waltham, Massachusetts with a ribbon cutting
ceremony arranged in collaboration with the Massachusetts Life Sciences Center
(MLSC).
"North America is an increasingly important region for Sobi, and building our
team in the Boston area supports us in our efforts to better address the needs
of patients and healthcare providers throughout the United States and Canada, "
says Geoffrey McDonough, Sobi's President & CEO. "We are delighted to partner
and collaborate with the Massachusetts Life Sciences Center as we build and grow
in the years to come."
Ceremony attendees included local officials and legislators, MLSC President &
CEO Susan Windham-Bannister, Ph.D., President, National Organization of Rare
Disorders, Dr. Peter Saltonstall, Manager of Business Development, Massachusetts
Office of International Trade & Investment Brittany McDonough, MassBio Director
of Economic Development & Global Affairs Peter Abair, as well as Sobi's
President & CEO, Geoffrey McDonough, and President North America, Rami Levin.
"Thanks to our growth strategy of investing in education, innovation and
infrastructure, and the extensive outreach efforts of the Massachusetts Life
Sciences Center, Massachusetts has become the destination of choice for
international life sciences companies that want to have a presence in the U.S.
market," said Governor Deval Patrick. "We welcome Sobi to their new offices in
Waltham and look forward to partnering with them as they grow."
"Massachusetts has one of the largest concentrations of biotech activity in the
world. The region has established a broad-based biotech industry segment, and
with Massachusetts as a major driver for global biotechnology innovation there
is a strong talent pool here. This is essential for us as we grow our North
American business," says Rami Levin, President, Sobi North America.
Sobi is a pioneer in biotechnology with world-class capabilities in protein
biochemistry and biologics manufacturing. In North America, the Company mainly
focuses on inflammatory, genetic, and metabolic diseases. Earlier this year,
Sobi assumed direct responsibility for the commercialization of its proprietary
product, Orfadin in North America. Orfadin is the only FDA approved therapy for
use as an adjunct to dietary restriction of tyrosine and phenylalanine for the
treatment of hereditary tyrosinemia type 1 (HT-1).
Sobi has worked closely with the Massachusetts Life Sciences Center when
developing their plans for their Massachusetts office.
"On behalf of the Center, I would like to extend a warm welcome to the team at
Sobi as they open their new North American headquarters in Waltham," said Susan
Windham-Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences
Center, the agency charged with implementing Governor Patrick's 10-year, $1
billion Life Sciences Initiative. "Sobi is an excellent addition to a growing
cluster of Massachusetts companies that are working to improve the lives of
patients with rare diseases. We are excited that Sobi has chosen Massachusetts
as the home of its North American headquarters and look forward to partnering
with the company as it grows."
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with two late stage biological
development projects within Haemophilia. We also market a portfolio of specialty
and rare disease products for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion
(?253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.
About the Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center (MLSC) is an investment agency that
supports life sciences innovation, research, development and commercialization.
The MLSC is charged with implementing a 10-year, $1-billion, state-funded
investment initiative. These investments create jobs and support advances that
improve health and well-being. The MLSC offers the nation's most comprehensive
set of incentives and collaborative programs targeted to the life sciences
ecosystem. These programs propel the growth that has made Massachusetts the
global leader in life sciences. The MLSC creates new models for collaboration
and partners with organizations, both public and private, around the world to
promote innovation in the life sciences. For more information, visit
www.masslifesciences.com.
MLSC Disclaimer: This announcement is not intended to be a commercial
endorsement of any products or services provided or developed by the entities
referenced in this release.
For more information please contact
Media relations Investor relations
Oskar Bosson Jörgen Winroth,
Head of Communications Vice President, Head of Investor
Relations
T: +46 70 410 71 80 T:
+1 347-224-0819, +1 212-579-050
oskar.bosson(at)sobi.com jorgen.winroth(at)sobi.com
Angus McQuilken
Vice President for Communications & Marketing
Massachusetts Life Sciences Center
Tel: +1-617 921-7749
amcquilken(at)masslifesciences.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via GlobeNewswire
[HUG#1857464]
Unternehmensinformation / Kurzprofil:
Datum: 22.09.2014 - 17:00 Uhr
Sprache: Deutsch
News-ID 342183
Anzahl Zeichen: 6785
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 170 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sobi opens North American operations"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
